Evidence map›Paper›PMID 39384966›Full record

ArticleScientific reports2024

Rejuvenation of human mesenchymal stem cells using a nonintegrative and conditionally removable Sendai virus vector.

Mitsuo Oshimura, Toshiaki Tabata, Narumi Uno, Shuta Takata, Genki Hichiwa, Iori Kanazawa, Takeshi Endo, Kazuhisa Honma, Yayan Wang, Kanako Kazuki and 4 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mitsuo OshimuraTrans Chromosomics Inc, 86 Nishi-cho, Yonago, 683-8503, Tottori, Japan.
Toshiaki TabataTottori Bio Frontier, 86 Nishi-cho, Yonago, 683-8503, Tottori, Japan.
Narumi UnoChromosome Engineering Research Center, Tottori University, 86 Nishi-cho, Yonago, 683-8503, Tottori, Japan.
Shuta TakataChromosome Engineering Research Center, Tottori University, 86 Nishi-cho, Yonago, 683-8503, Tottori, Japan.
Genki HichiwaChromosome Engineering Research Center, Tottori University, 86 Nishi-cho, Yonago, 683-8503, Tottori, Japan.
Iori KanazawaTrans Chromosomics Inc, 86 Nishi-cho, Yonago, 683-8503, Tottori, Japan.
Takeshi EndoTrans Chromosomics Inc, 86 Nishi-cho, Yonago, 683-8503, Tottori, Japan.
Kazuhisa HonmaTrans Chromosomics Inc, 86 Nishi-cho, Yonago, 683-8503, Tottori, Japan.
Yayan WangDepartment of Chromosome Biomedical Engineering, Integrated Medical Sciences, Graduate School of Medical Sciences, Tottori University, 86 Nishi-cho, Yonago, 683-8503, Tottori, Japan.
Kanako KazukiChromosome Engineering Research Center, Tottori University, 86 Nishi-cho, Yonago, 683-8503, Tottori, Japan.
Haochen TuDepartment of Chromosome Biomedical Engineering, Integrated Medical Sciences, Graduate School of Medical Sciences, Tottori University, 86 Nishi-cho, Yonago, 683-8503, Tottori, Japan.
Yuichi IidaChromosome Engineering Research Center, Tottori University, 86 Nishi-cho, Yonago, 683-8503, Tottori, Japan.
Satoshi AbeChromosome Engineering Research Center, Tottori University, 86 Nishi-cho, Yonago, 683-8503, Tottori, Japan.
Yasuhiro KazukiChromosome Engineering Research Center, Tottori University, 86 Nishi-cho, Yonago, 683-8503, Tottori, Japan. kazuki@tottori-u.ac.jp.

Funding

AMED JP24bm1123038ExCELLS 21-101JST CREST JPMJCR18S4
6 · The paper itself

Abstract

Human mesenchymal stem cells (hMSCs) with extended lifespan and differentiation potential that can recapitulate in vivo characteristics could significantly contribute to basic research, drug development, and cell therapy. Specifically, they could ensure a stable supply of specific cellular resources, and possibly extracellular vesicles. Here, we established a technology for extending the lifespan while maintaining differentiation potential, termed "rejuvenation," of hMSCs (rej-hMSCs) using nonintegrative and conditionally removable temperature-sensitive Sendai virus (SeV) vectors. Various immortalizing factors (i.e., Bmi-1, hTERT, SV40T, and/or HPV E6/E7) were first introduced by the SeV vector into the cells. A combination of three SeVs with Bmi-1, hTERT, or SV40T conferred markedly improved cell proliferation and cloning ability while maintaining differentiation potential and a normal karyotype. An extended lifespan was also demonstrated in other cell types. The rejuvenation of long-passaged or aged hMSCs was also confirmed. SeV vectors were rapidly removed as a function of cell doubling by increasing the temperature from 35 °C to 37 °C or higher, while proliferative ability was maintained. Following FACS sorting, the complete removal of SeV vectors was confirmed by qPCR analyses. Therefore, our cell rejuvenation technology could contribute to research and clinical applications by enabling the supply of modified cells without damaging host chromosomes.

Indexed as

Cell DifferentiationCell ProliferationGenetic VectorsMesenchymal Stem CellsSendai virusCells, CulturedHumansPolycomb Repressive Complex 1RejuvenationTelomerasePolycomb Repressive Complex 1TelomeraseTERT protein, humanExtended lifespanHuman mesenchymal stem cellRegenerative medicineRejuvenationSendai virus vector

Identifiers

PMID39384966
PMCPMC11464914

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.